UDP-glucuronosyltransferase 2B7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes

被引:17
作者
Bauman, JN
Goosen, TC
Tugnait, M
Peterkin, V
Hurst, SI
Menning, LC
Milad, M
Court, MH
Williams, JA
机构
[1] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Ann Arbor, MI 48105 USA
[2] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
关键词
D O I
10.1124/dmd.105.005108
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The predominant metabolic pathway of gemcabene in humans is glucuronidation. The principal human UDP-glucuronosyltransferases (UGTs) involved in the glucuronidation of gemcabene were determined in this study. Glucuronidation of gemcabene was catalyzed by recombinant UGT1A3, recombinant UGT2B7, and recombinant UGT2B17, as well as by human liver microsomes (HLM). Gemcabene glucuronidation in recombinant UGTs and HLM followed non-Michaelis-Menten kinetics consistent with homotropic activation, but pharmacokinetics in humans were linear over the dose range tested ( total plasma C-max, 0.06-0.88 mM). Gemcabene showed similar affinity (S-50) for recombinant UGTs (0.92-1.45 mM) and HLM (1.37 mM). S-Flurbiprofen was identified as a more selective inhibitor of recombinant UGT2B7-catalyzed gemcabene glucuronidation (>23-fold lower IC50) when compared with recombinant UGT1A3- or recombinant UGT2B17-catalyzed gemcabene glucuronidation. The IC50 for S-flurbiprofen inhibition of gemcabene glucuronidation was similar in HLM (60.6 mu M) compared with recombinant UGT2B7 (27.4 mu M), consistent with a major role for UGT2B7 in gemcabene glucuronidation in HLM. In addition, 5,6,7,3',4',5'-hexamethoxyflavone inhibited recombinant UGT1A3 and recombinant UGT2B17-catalyzed gemcabene glucuronidation ( with 4-fold greater potency for recombinant UGT1A3) but did not inhibit gemcabene glucuronidation in HLM, suggesting that UGT1A3 and UGT2B17 do not contribute significantly to gemcabene glucuronidation. Reaction rates for gemcabene glucuronidation from a human liver bank correlated well (r(2) = 0.722, P < 0.0001; n = 24) with rates of glucuronidation of the UGT2B7 probe substrate 3'-azido-3'-deoxythymidine. In conclusion, using the three independent experimental approaches typically used for cytochrome P440 reaction phenotyping, UGT2B7 is the major enzyme contributing to gemcabene glucuronidation in human liver microsomes.
引用
收藏
页码:1349 / 1354
页数:6
相关论文
共 14 条
[1]
Pharmacotherapy for dyslipidaemia - current therapies and future agents [J].
Bays, H ;
Stein, EA .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) :1901-1938
[2]
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[3]
In vitro assessment of human cytochrome P450 [J].
Clarke, SE .
XENOBIOTICA, 1998, 28 (12) :1167-1202
[4]
Court MH, 2004, METHOD PHARMACOL TOX, P185
[5]
In vitro and pharmacophore insights into CYP3A enzymes [J].
Ekins, S ;
Stresser, DM ;
Williams, JA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (04) :161-166
[6]
The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence [J].
Mackenzie, PI ;
Owens, IS ;
Burchell, B ;
Bock, KW ;
Bairoch, A ;
Belanger, A ;
FournelGigleux, S ;
Green, M ;
Hum, DW ;
Iyanagi, T ;
Lancet, D ;
Louisot, P ;
Magdalou, J ;
Chowdhury, JR ;
Ritter, JK ;
Schachter, H ;
Tephly, TR ;
Tipton, KF ;
Nebert, DW .
PHARMACOGENETICS, 1997, 7 (04) :255-269
[7]
Predicting human drug glucuronidation parameters: Application of in vitro and in silico modeling approaches [J].
Miners, JO ;
Smith, PA ;
Sorich, MJ ;
McKinnon, RA ;
Mackenzie, PI .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 :1-25
[8]
Structural and functional studies of UDP-glucuronosyltransferases [J].
Radominska-Pandya, A ;
Czernik, PJ ;
Little, JM ;
Battaglia, E ;
Mackenzie, PI .
DRUG METABOLISM REVIEWS, 1999, 31 (04) :817-899
[9]
Segel IH, 1975, Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems
[10]
INVESTIGATION OF THE SUBSTRATE-SPECIFICITY OF A CLONED EXPRESSED HUMAN BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE - UDP-SUGAR SPECIFICITY AND INVOLVEMENT IN STEROID AND XENOBIOTIC GLUCURONIDATION [J].
SENAFI, SB ;
CLARKE, DJ ;
BURCHELL, B .
BIOCHEMICAL JOURNAL, 1994, 303 :233-240